Giuseppe Pantaleo

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


449 publications

En préparation
 
Distinct immune signatures are a potent tool in the clinical management of cytokine-related syndrome during immune checkpoint therapy
Daoudlarian Douglas, Segot Amandine, Latifyan Sofiya, Bartolini Robin, Joo Victor, Mederos Nuria, Bouchaab Hasna, Demicheli Rita, Abdelhamid Karim, Ferahta Nabila et al..
[DOI][serval:BIB_818D0F24F67B]
 
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study
Petit Pierre-Florent, Daoudlarian Douglas, Latifyan Sofiya, Bouchaab Hasna, Mederos Nuria, Doms Jacqueline, Abdelhamid Karim, Ferahta Nabila, Mencarelli Lucrezia, Joo Victor et al..
[DOI][serval:BIB_34BED0C92D50]
In press
 
Subunit protein CD40.SARS.CoV2 vaccine induces SARS-CoV-2-specific stem cell-like memory CD8<sup>+</sup> T cells.
Nguema L., Picard F., El Hajj M., Dupaty L., Fenwick C., Cardinaud S., Wiedemann A., Pantaleo G., Zurawski S., Centlivre M. et al. EBioMedicine. Peer-reviewed.
[DOI][Pmid][serval:BIB_06AED805F232]
2024
 
Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06).
Levy Y., Moog C., Wiedemann A., Launay O., Candotti F., Hardel L., Durand M., Rieux V., Diallo A., Lacabaratz C. et al., 2024/11. EClinicalMedicine, 77 p. 102845. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_40E7F12D27D8]
 
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study.
Petit P.F., Daoudlarian D., Latifyan S., Bouchaab H., Mederos N., Doms J., Abdelhamid K., Ferahta N., Mencarelli L., Joo V. et al., 2024/09/04. Annals of oncology. Peer-reviewed.
[DOI][Pmid][serval:BIB_0BA6393BFB37]
Follicular Immune Landscaping Reveals a Distinct Profile of FOXP3<sup>hi</sup>CD4<sup>hi</sup> T Cells in Treated Compared to Untreated HIV.
Georgakis S., Orfanakis M., Brenna C., Burgermeister S., Del Rio Estrada P.M., González-Navarro M., Torres-Ruiz F., Reyes-Terán G., Avila-Rios S., Luna-Villalobos Y.A. et al., 2024/08/12. Vaccines, 12 (8). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6F34C11CEE24]
 
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial.
Garrett N., Dintwe O., Monaco C.L., Jones M., Seaton K.E., Church E.C., Grunenberg N., Hutter J., deCamp A., Huang Y. et al., 2024/08/01. Journal of acquired immune deficiency syndromes, 96 (4) pp. 350-360. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D713D414CFEE]
 
Is HIV epidemic control by 2030 realistic?
Beyrer C., Tomaras G.D., Gelderblom H.C., Gray G.E., Janes H.E., Bekker L.G., Millett G., Pantaleo G., Buchbinder S., Corey L., 2024/07. The lancet. HIV, 11 (7) pp. e489-e494. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7A1AFFD30706]
 
Deep mapping of the cytokine release syndrome inflammatory continuum: Comprehensive grade-specific profiling and differentiation from sepsis in patients receiving immune checkpoint therapy.
Obeid Michel, Daoudlarian Douglas, Segot Amandine, Latifyan Sofiya, Bouchaab Hasna, Mederos Nuria, Abdelhamid Karim, Ferahta Nabila, Stravodimou Athina, Shabafrouz Keyvan et al., 2024/06/01. Journal of Clinical Oncology, 42 (16_suppl) pp. 12129-12129.
[DOI][serval:BIB_928272EB14D0]
 
High-dimensional longitudinal immune profiling uncovers a dual role of the CXCL9/CXCR3, CXCL13/CXCR5, and CCL11/CCL3 axis in the coupling of immune-related adverse events to immune checkpoint inhibitor response.
Obeid Michel, Joo Victor, Daoudlarian Douglas, Bartolini Robin, Bouchaab Hasna, Latifyan Sofiya, Mederos Nuria, Abdelhamid Karim, Mosimann Valérie, Ferahta Nabila et al., 2024/06/01. Journal of Clinical Oncology, 42 (16_suppl) pp. 2512-2512.
[DOI][serval:BIB_DDD63EA0571E]
 
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial.
Walsh S.R., Gay C.L., Karuna S.T., Hyrien O., Skalland T., Mayer K.H., Sobieszczyk M.E., Baden L.R., Goepfert P.A., Del Rio C. et al., 2024/06. PLoS medicine, 21 (6) pp. e1004329. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5633EE3B4E64]
Pilot Study of sC5b-9 and Bb Fragment Plasma Levels in Crescentic Immunoglobulin A Nephropathy.
Guzzo G., Sadallah S., Rousson V., Herrera-Gómez F., Pantaleo G., Pascual M., Teta D., 2024/05. Kidney international reports, 9 (5) pp. 1517-1520. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E09E9C8D368F]
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.
Joo V., Abdelhamid K., Noto A., Latifyan S., Martina F., Daoudlarian D., De Micheli R., Pruijm M., Peters S., Hullin R. et al., 2024/04/30. Nature communications, 15 (1) p. 3664. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4D3A2A46F635]
Residual Partial Least Squares Learning: Brain Cortical Thickness Simultaneously Predicts Eight Non-pairwise-correlated Behavioural and Disease Outcomes in Alzheimer's Disease.
Chén O.Y., Vũ D.T., Diaz C.S., Bodelet J.S., Phan H., Allali G., Nguyen V.D., Cao H., He X., Müller Y. et al., 2024/03/27..
[URN][DOI][Pmid][serval:BIB_3B332933DA5C]
Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial.
Manuel O., Laager M., Hirzel C., Neofytos D., Walti L.N., Hoenger G., Binet I., Schnyder A., Stampf S., Koller M. et al., 2024/02/17. Clinical infectious diseases, 78 (2) pp. 312-323. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AA450EA2BB8A]
Myeloid-Derived Suppressor-like Cells as a Prognostic Marker in Critically Ill Patients: Insights from Experimental Endotoxemia and Intensive Care Patients.
Schrijver I.T., Herderschee J., Théroude C., Kritikos A., Leijte G., Le Roy D., Brochut M., Chiche J.D., Perreau M., Pantaleo G. et al., 2024/02/08. Cells, 13 (4). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AAE7B79746C8]
A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies.
Moullan N., Asiago J., Stecco K., Hadi S., Albizem M., Tieu H., Hock B., Fenwick C., Lin K., Lengsfeld T. et al., 2024/01. Infectious diseases and therapy, 13 (1) pp. 173-187. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_890F055350A3]
 
Editorial introductions
Pantaleo Giuseppe, Deeks Steven G., Alba Diana, 2024/01. Current Opinion in HIV and AIDS, 19 (1) pp. V-VI.
[DOI][WoS][serval:BIB_4BCD8844162A]
 
SWIFT clustering analysis of intracellular cytokine staining flow cytometry data of the HVTN 105 vaccine trial reveals high frequencies of HIV-specific CD4+ T cell responses and associations with humoral responses.
Mosmann T.R., Rebhahn J.A., De Rosa S.C., Keefer M.C., McElrath M.J., Rouphael N.G., Pantaleo G., Gilbert P.B., Corey L., Kobie J.J. et al., 2024. Frontiers in immunology, 15 p. 1347926. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9E90934C264D]
2023
Development of hybrid immunity during a period of high incidence of Omicron infections.
Frei A., Kaufmann M., Amati R., Butty Dettwiler A., von Wyl V., Annoni A.M., Vincentini J., Pellaton C., Pantaleo G., Fehr J.S. et al., 2023/12/25. International journal of epidemiology, 52 (6) pp. 1696-1707. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_58F5CD0974E9]
 
Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys.
Fenwick C., Turelli P., Duhoo Y., Lau K., Herate C., Marlin R., Lamrayah M., Campos J., Esteves-Leuenberger L., Farina A. et al., 2023/12. The Journal of infection, 87 (6) pp. 524-537. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0A69FF2015C1]
Persistent humoral immune response in youth throughout the COVID-19 pandemic: prospective school-based cohort study.
Raineri A., Radtke T., Rueegg S., Haile S.R., Menges D., Ballouz T., Ulyte A., Fehr J., Cornejo D.L., Pantaleo G. et al., 2023/11/27. Nature communications, 14 (1) p. 7764. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BDC2C0B508CE]
Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ART.
Banga R., Procopio F.A., Lana E., Gladkov G.T., Roseto I., Parsons E.M., Lian X., Armani-Tourret M., Bellefroid M., Gao C. et al., 2023/10/11. Cell host & microbe, 31 (10) pp. 1714-1731.e9. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9F739E97B9B6]
 
80 C5b-9 and Bb factor levels as potential novel biomarkers in crescentic IgA nephropathy
Guzzo Gabriella, Sadallah Salima, Pantaleo Giuseppe, Pascual Manuel, Teta Daniel, 2023/09., XXIX (29th) International Complement Workshop 2023 p. 152531 dans Immunobiology.
[DOI][WoS][serval:BIB_5C66C94BEBD0]
HIV specific Th1 responses are altered in Ugandans with HIV and Schistosoma mansoni coinfection.
Obuku A.E., Lugemwa J.K., Abaasa A., Joloba M., Ding S., Pollara J., Ferrari G., Harari A., Pantaleo G., Kaleebu P., 2023/08/29. BMC immunology, 24 (1) p. 25. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_62C12F4E0858]
Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients.
Fallet B., Foglierini M., Porret R., Alcaraz-Serna A., Sauvage C., Jenelten R., Caplanusi T., Gilliet M., Perez L., Fenwick C. et al., 2023/08. The Journal of infection, 87 (2) pp. 111-119. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9DA429039D3E]
The Statistical Analysis of the Varying Brain.
Chén Oliver Y., Thanh Vũ Duy, Greub Gilbert, Cao Hengyi, He Xingru, Muller Yannick, Petrovas Constantinos, Shou Haochang, Nguyen Viet-Dung, Zhi Bangdong et al., 2023/07/02. IEEE Statistical Signal Processing (SSP). Peer-reviewed.
[URN][DOI][WoS][serval:BIB_C6B3B6AA1F8B]
Correction to: Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID‑19.
Hocini H., Wiedemann A., Blengio F., Lefebvre C., Cervantes-Gonzalez M., Foucat E., Tisserand P., Surenaud M., Coléon S., Prague M. et al., 2023/07. Journal of clinical immunology, 43 (5) p. 894. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E5F153F4367A]
Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19.
Hocini H., Wiedemann A., Blengio F., Lefebvre C., Cervantes-Gonzalez M., Foucat E., Tisserand P., Surenaud M., Coléon S., Prague M. et al., 2023/07. Journal of clinical immunology, 43 (5) pp. 882-893. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_30D621CDC238]
Association of plasma zinc levels with anti-SARS-CoV-2 IgG and IgA seropositivity in the general population: A case-control study.
Equey A., Berger M.M., Gonseth-Nusslé S., Augsburger M., Rezzi S., Hodgson ACC, Estoppey S., Pantaleo G., Pellaton C., Perrais M. et al., 2023/04/18. Clinical nutrition, 42 (6) pp. 972-986. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BEE6C76A8AC7]
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults.
Cohen K.W., Fiore-Gartland A., Walsh S.R., Yusim K., Frahm N., Elizaga M.L., Maenza J., Scott H., Mayer K.H., Goepfert P.A. et al., 2023/02/15. The Journal of clinical investigation, 133 (4) pp. e163338. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4401BE6482F7]
A CD64/FcγRI-mediated mechanism hijacks PD-1 from PD-L1/2 interaction and enhances anti-PD-1 functional recovery of exhausted T cells.
Joo V., Petrovas C., de Leval L., Noto A., Obeid M., Fenwick C., Pantaleo G., 2023. Frontiers in immunology, 14 p. 1213375. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_431B1ABF3E8A]
Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein.
Perdiguero B., Hauser A., Gómez C.E., Peterhoff D., Sideris E., Sorzano CÓS, Wilmschen S., Schaber M., Stengel L., Asbach B. et al., 2023. Frontiers in immunology, 14 p. 1270908. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D789F3FAEA8A]
Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial.
Stalder G., Suffiotti M., Segot A., Noto A., Pantaleo G., Spertini O., Obeid M., 2023/01/01. Haematologica, 108 (1) pp. 234-239. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5551F9C73188]
SARS-CoV-2 neutralizing antibody response in vaccinated and non-vaccinated hospital healthcare workers with or without history of infection.
Jacot D., von Rotz U., Pellaton C., Blondet F., Aebischer O., Perreau M., De Rham M., Pantaleo G., Marchetti O., Greub G., 2023. Microbes and infection, 25 (1-2) p. 105077. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_35EA6DCB0511]
2022
CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses.
Noto A., Joo V., Mancarella A., Suffiotti M., Pellaton C., Fenwick C., Perreau M., Pantaleo G., 2022/11/28. Viruses, 14 (12) p. 2665. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1C95F51CD2B0]
COVID-19 rapidly increases MDSCs and prolongs innate immune dysfunctions.
Schrijver I.T., Théroude C., Antonakos N., Regina J., Le Roy D., Bart P.A., Chiche J.D., Perreau M., Pantaleo G., Calandra T. et al., 2022/10. European journal of immunology, 52 (10) pp. 1676-1679. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CE51282F926C]
Antibodies to combat viral infections: development strategies and progress.
Pantaleo G., Correia B., Fenwick C., Joo V.S., Perez L., 2022/09. Nature reviews. Drug discovery, 21 (9) pp. 676-696. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_09F440C68729]
 
Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys.
Fenwick C., Turelli P., Ni D., Perez L., Lau K., Herate C., Marlin R., Lana E., Pellaton C., Raclot C. et al., 2022/09. Nature microbiology, 7 (9) pp. 1376-1389. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_539E1A543541]
Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort.
Menges D., Zens K.D., Ballouz T., Caduff N., Llanas-Cornejo D., Aschmann H.E., Domenghino A., Pellaton C., Perreau M., Fenwick C. et al., 2022/08/18. Nature communications, 13 (1) p. 4855. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F6D33AB61943]
Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022.
Amati R., Frei A., Kaufmann M., Sabatini S., Pellaton C., Fehr J., Albanese E., Puhan M.A., Corona Immunitas Research Group, 2022/08. Euro surveillance, 27 (31). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6DDFE21CA95A]
 
SARS-CoV-2 seroprevalence in hospital healthcare workers in Western Switzerland at the end of the second pandemic wave.
Jacot D., von Rotz U., Blondet F., Aebischer O., Matthieu P., De Rham M., Pantaleo G., Marchetti O., Greub G., 2022/08. Journal of medical microbiology, 71 (8). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2E339D4530BF]
Multifocal lymphadenopathies with polyclonal reactions primed after EBV infection in a mRNA-1273 vaccine recipient.
Girardin F.R., Tzankov A., Pantaleo G., Livio F., Greub G., 2022/05/23. Swiss medical weekly, 152 pp. w30188. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_378A2D414165]
Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19.
Kritikos A., Gabellon S., Pagani J.L., Monti M., Bochud P.Y., Manuel O., Coste A., Greub G., Perreau M., Pantaleo G. et al., 2022/05/18. Viruses, 14 (5) p. 1089. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7AA364497D07]
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M., Suffiotti M., Pellaton C., Bouchaab H., Cairoli A., Salvadé V., Stevenel C., Hottinger R., Pythoud C., Coutechier L. et al., 2022/05/01. JAMA oncology, 8 (5) pp. e220446. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8956034C5615]
Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period.
Lazor-Blanchet C., Zygoura P., Dafni U., Lamoth F., Tsourti Z., Lobritz M.A., Regina J., Grandbastien B., Fenwick C., Pantaleo G. et al., 2022/05. The Journal of infection, 84 (5) pp. 722-746. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB5408AF350D]
High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus.
Herderschee J., Heinonen T., Fenwick C., Schrijver I.T., Ohmiti K., Moradpour D., Cavassini M., Pantaleo G., Roger T., Calandra T. et al., 2022/04. Clinical microbiology and infection, 28 (4) pp. 611.e1-611.e7. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_300AF1BADC64]
 
SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique Spike binding properties
Fenwick Craig, Turelli Priscilla, Ni Dongchun, Perez Laurent, Lau Kelvin, Lana Erica, Pellaton Céline, Raclot Charlène, Esteves-Leuenberger Line, Campos Jérémy et al., 2022/03..
[DOI][serval:BIB_938CCD54F9CA]
Human macrophages and monocyte-derived dendritic cells stimulate the proliferation of endothelial cells through midkine production.
Said E.A., Al-Dughaishi S., Al-Hatmi W., Al-Reesi I., Al-Riyami M., Al-Balushi M.S., Al-Bimani A., Al-Busaidi J.Z., Al-Khabori M., Al-Kindi S. et al., 2022. PloS one, 17 (4) pp. e0267662. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_31DADE94BC9B]
Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients.
Wiedemann A., Pellaton C., Dekeyser M., Guillaumat L., Déchenaud M., Krief C., Lacabaratz C., Grimbert P., Pantaleo G., Lévy Y. et al., 2022. Frontiers in medicine, 9 p. 978764. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3A74857F7FD8]
The deficiency in Th2-like Tfh cells affects the maturation and quality of HIV-specific B cell response in viremic infection.
Noto A., Suffiotti M., Joo V., Mancarella A., Procopio F.A., Cavet G., Leung Y., Corpataux J.M., Cavassini M., Riva A. et al., 2022. Frontiers in immunology, 13 p. 960120. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3A9147719CB5]
2021
Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials.
Fischinger S., Cizmeci D., Deng D., Grant S.P., Frahm N., McElrath J., Fuchs J., Bart P.A., Pantaleo G., Keefer M. et al., 2021/11. PLoS pathogens, 17 (11) pp. e1010016. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F1241293379B]
A highly potent antibody effective against SARS-CoV-2 variants of concern.
Fenwick C., Turelli P., Perez L., Pellaton C., Esteves-Leuenberger L., Farina A., Campos J., Lana E., Fiscalini F., Raclot C. et al., 2021/10/12. Cell reports, 37 (2) p. 109814. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6CC56B59453A]
 
Reactivation of IgA vasculitis after COVID-19 vaccination.
Obeid M., Fenwick C., Pantaleo G., 2021/09. The Lancet. Rheumatology, 3 (9) pp. e617. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1D8F6DD0B85B]
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques.
Marlin R., Godot V., Cardinaud S., Galhaut M., Coleon S., Zurawski S., Dereuddre-Bosquet N., Cavarelli M., Gallouët A.S., Maisonnasse P. et al., 2021/09/01. Nature communications, 12 (1) p. 5215. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_90B177569A3B]
The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients.
Perreau M., Suffiotti M., Marques-Vidal P., Wiedemann A., Levy Y., Laouénan C., Ghosn J., Fenwick C., Comte D., Roger T. et al., 2021/08/09. Nature communications, 12 (1) p. 4888. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D985FAB1BA6B]
A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma.
Fenwick C., Turelli P., Pellaton C., Farina A., Campos J., Raclot C., Pojer F., Cagno V., Nusslé S.G., D'Acremont V. et al., 2021/08/04. Science translational medicine, 13 (605) pp. eabi8452. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DB7C1B80A401]
Eculizumab as a New Treatment for Severe Acute Post-infectious Glomerulonephritis: Two Case Reports.
Chehade H., Guzzo G., Cachat F., Rotman S., Teta D., Pantaleo G., Sadallah S., Sharma A., Rosales I.A., Tolkoff-Rubin N. et al., 2021/07/31. Frontiers in medicine, 8 p. 663258. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_78558A2B0C1B]
CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.
Lévy Y., Wiedemann A., Hejblum B.P., Durand M., Lefebvre C., Surénaud M., Lacabaratz C., Perreau M., Foucat E., Déchenaud M. et al., 2021/07/23. iScience, 24 (7) p. 102711. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_909F730EC11C]
Complement activation and blockade in massive post-partum haemorrhage, thrombotic microangiopathy and acute kidney injury: a case report.
Guzzo G., Kissling S., Pantaleo G., Pascual M., Sadallah S., Teta D., 2021/07/06. BMC nephrology, 22 (1) p. 252. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5BD58C2F1EDF]
SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study.
Meylan S., Dafni U., Lamoth F., Tsourti Z., Lobritz M.A., Regina J., Bressin P., Senn L., Grandbastien B., Andre C. et al., 2021/07/05. BMJ open, 11 (7) pp. e049232. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_471F833F0211]
Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation.
Bernard-Valnet R., Perriot S., Canales M., Pizzarotti B., Caranzano L., Castro-Jiménez M., Epiney J.B., Vijiala S., Salvioni-Chiabotti P., Anichini A. et al., 2021/07. Neurology, 8 (5) pp. e1029. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2403F6DD5AAC]
 
Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.
Dupraz J., Butty A., Duperrex O., Estoppey S., Faivre V., Thabard J., Zuppinger C., Greub G., Pantaleo G., Pasquier J. et al., 2021/07. Open forum infectious diseases, 8 (7) pp. ofab149. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FDA752E9104B]
 
Acquisition of optimal TFH cell function is defined by specific molecular, positional, and TCR dynamic signatures.
Padhan K., Moysi E., Noto A., Chassiakos A., Ghneim K., Perra M.M., Shah S., Papaioannou V., Fabozzi G., Ambrozak D.R. et al., 2021/05/04. Proceedings of the National Academy of Sciences of the United States of America, 118 (18) pp. e2016855118. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4A4C000AF4D9]
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans.
Seaton K.E., Deal A., Han X., Li S.S., Clayton A., Heptinstall J., Duerr A., Allen M.A., Shen X., Sawant S. et al., 2021/04/15. NPJ vaccines, 6 (1) p. 56. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F71F6A9EA243]
A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
Lévy Y., Lacabaratz C., Lhomme E., Wiedemann A., Bauduin C., Fenwick C., Foucat E., Surenaud M., Guillaumat L., Boilet V. et al., 2021/04/12. Journal of virology, 95 (9) pp. e02165-20. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6673B3848E48]
 
Implementing SARS-CoV-2 Rapid Antigen Testing in the Emergency Ward of a Swiss University Hospital: The INCREASE Study.
Caruana G., Croxatto A., Kampouri E., Kritikos A., Opota O., Foerster M., Brouillet R., Senn L., Lienhard R., Egli A. et al., 2021/04/10. Microorganisms, 9 (4) p. 798. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0FC767B1B433]
In Situ Characterization of Follicular Helper CD4 T Cells Using Multiplexed Imaging.
Ioannidou K., Ndiaye D.R., Noto A., Fenwick C., Fortis S.P., Pantaleo G., Petrovas C., de Leval L., 2021/02/28. Frontiers in immunology, 11 p. 607626. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0018D6BF0D49]
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
Hosseinipour M.C., Innes C., Naidoo S., Mann P., Hutter J., Ramjee G., Sebe M., Maganga L., Herce M.E., deCamp A.C. et al., 2021/01/23. Clinical infectious diseases, 72 (1) pp. 50-60. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_51B64C338E47]
Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies.
Fenwick C., Croxatto A., Coste A.T., Pojer F., André C., Pellaton C., Farina A., Campos J., Hacker D., Lau K. et al., 2021/01/13. Journal of virology, 95 (3) pp. e01828-20. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_95BA21CCB9C1]
Case Report: A Rare Truncating Variant of the CFHR5 Gene in IgA Nephropathy.
Guzzo G., Sadallah S., Fodstad H., Venetz J.P., Rotman S., Teta D., Gauthier T., Pantaleo G., Superti-Furga A., Pascual M., 2021. Frontiers in genetics, 12 p. 529236. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AA15A6D9CD84]
Case Report: SARS-CoV-2 as an unexpected causal agent of predominant febrile hepatitis.
Filippidis P., van Ouwenaller F., Cerutti A., Geiger-Jacquod A., Sempoux C., Pantaleo G., Moradpour D., Lamoth F., 2021. F1000Research, 10 p. 400. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0194C4870252]
2020
TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice.
Godot V., Tcherakian C., Gil L., Cervera-Marzal I., Li G., Cheng L., Ortonne N., Lelièvre J.D., Pantaleo G., Fenwick C. et al., 2020/11. PLoS pathogens, 16 (11) pp. e1009025. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_772249C57318]
Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA.
Lungu C., Procopio F.A., Overmars R.J., Beerkens RJJ, Voermans JJC, Rao S., Prins HAB, Rokx C., Pantaleo G., Vijver DAMCV et al., 2020/09/02. Viruses, 12 (9) pp. E973. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FA8B8D55233A]
 
Blood and Lymph Node Dissemination of Clonal Genome-Intact Human Immunodeficiency Virus 1 DNA Sequences During Suppressive Antiretroviral Therapy.
Kuo H.H., Banga R., Lee G.Q., Gao C., Cavassini M., Corpataux J.M., Blackmer J.E., Zur Wiesch S., Yu X.G., Pantaleo G. et al., 2020/07/23. The Journal of infectious diseases, 222 (4) pp. 655-660. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D6B879F20B5C]
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.
Lévy Y., Lacabaratz C., Ellefsen-Lavoie K., Stöhr W., Lelièvre J.D., Bart P.A., Launay O., Weber J., Salzberger B., Wiedemann A. et al., 2020/06. PLoS pathogens, 16 (6) pp. e1008522. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_82AFFC2A801F]
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
Moodie Z., Walsh S.R., Laher F., Maganga L., Herce M.E., Naidoo S., Hosseinipour M.C., Innes C., Bekker L.G., Grunenberg N. et al., 2020/05. PLoS medicine, 17 (5) pp. e1003117. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_69F33465D212]
 
The complex challenges of HIV vaccine development require renewed and expanded global commitment.
Bekker L.G., Tatoud R., Dabis F., Feinberg M., Kaleebu P., Marovich M., Ndung'u T., Russell N., Johnson J., Luba M. et al., 2020/02/01. Lancet, 395 (10221) pp. 384-388. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1C05F2A23A5B]
2019
Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector.
Giel-Moloney M., Esteban M., Oakes B.H., Vaine M., Asbach B., Wagner R., Mize G.J., Spies A.G., McElrath J., Perreau M. et al., 2019/12/27. Scientific reports, 9 (1) p. 20005. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_576063A9C68A]
 
A Robust Method for Assaying the Immunoreactive Fraction in Nonequilibrium Systems.
Denoël T., Pedrelli L., Pantaleo G., Prior J.O., 2019/12/03. Pharmaceuticals, 12 (4) pp. E177. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E07AD7079702]
 
Detection of Human Immunodeficiency Virus Type 1 (HIV-1) Antisense Protein (ASP) RNA Transcripts in Patients by Strand-Specific RT-PCR.
Mancarella A., Procopio F.A., Achsel T., De Crignis E., Foley B.T., Corradin G., Bagni C., Pantaleo G., Graziosi C., 2019/11/27. Journal of visualized experiments 153. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_639747930934]
 
Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial
Kallas E.G., Grunenberg N.A., Yu C., Manso B., Pantaleo G., Casapia M., Baden L.R., Valencia J., Sobieszczyk M., Van Tieu H. et al., 2019/11/20. Science translational medicine, 11 (519) pp. eaaw1673. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7B3B2ADF9DB1]
Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01.
Pinto D., Fenwick C., Caillat C., Silacci C., Guseva S., Dehez F., Chipot C., Barbieri S., Minola A., Jarrossay D. et al., 2019/11/13. Cell host & microbe, 26 (5) pp. 623-637.e8. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EBC683B64355]
DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial.
Rouphael N.G., Morgan C., Li S.S., Jensen R., Sanchez B., Karuna S., Swann E., Sobieszczyk M.E., Frank I., Wilson G.J. et al., 2019/11/01. The Journal of clinical investigation, 129 (11) pp. 4769-4785. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2E96704E07E0]
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.
Pantaleo G., Janes H., Karuna S., Grant S., Ouedraogo G.L., Allen M., Tomaras G.D., Frahm N., Montefiori D.C., Ferrari G. et al., 2019/11. The lancet. HIV, 6 (11) pp. e737-e749. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0F89E125D865]
T-cell exhaustion in HIV infection.
Fenwick C., Joo V., Jacquier P., Noto A., Banga R., Perreau M., Pantaleo G., 2019/11. Immunological reviews, 292 (1) pp. 149-163. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_09E2A0F1A53D]
Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion
Ascione A., Arenaccio C., Mallano A., Flego M., Gellini M., Andreotti M., Fenwick C., Pantaleo G., Vella S., Federico M., 2019/10/17. BMC biotechnology, 19 (1) p. 67. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_712A491B51BD]
Safety and tolerance of lymph node biopsies from chronic HIV-1 volunteers in rural Tanzania.
Mkindi C.G., Marandu E.A., Masawa N., Bani F., Nyuri A., Byakuzana T., Klimkait T., Ding S., Pantaleo G., Battegay M. et al., 2019/09/06. BMC research notes, 12 (1) p. 561. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9D7B18565C63]
 
Corrigendum to “A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles” [Virology 507 (2017) 242–256]
Meador Lydia R., Kessans Sarah A., Kilbourne Jacquelyn, Kibler Karen V., Pantaleo Giuseppe, Esteban Mariano, Blattman Joseph N., Jacobs Bertram L., Mor Tsafrir S., 2019/08. 143.
[DOI][WoS][Pmid][serval:BIB_4CBAA702B57A]
Lymph node migratory dendritic cells modulate HIV-1 transcription through PD-1 engagement.
Banga R., Rebecchini C., Procopio F.A., Noto A., Munoz O., Ioannidou K., Fenwick C., Ohmiti K., Cavassini M., Corpataux J.M. et al., 2019/07. PLoS pathogens, 15 (7) pp. e1007918. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1FF4BBBC8958]
Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway.
Fenwick C., Loredo-Varela J.L., Joo V., Pellaton C., Farina A., Rajah N., Esteves-Leuenberger L., Decaillon T., Suffiotti M., Noto A. et al., 2019/07/01. The Journal of experimental medicine, 216 (7) pp. 1525-1541. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0B420592FE76]
Detection of antisense protein (ASP) RNA transcripts in individuals infected with human immunodeficiency virus type 1 (HIV-1).
Mancarella A., Procopio F.A., Achsel T., De Crignis E., Foley B.T., Corradin G., Bagni C., Pantaleo G., Graziosi C., 2019/05. The Journal of general virology, 100 (5) pp. 863-876. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4178D396A6C4]
 
Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions.
Moore C.L., Stöhr W., Crook A.M., Richert L., Leliévre J.D., Pantaleo G., García F., Vella S., Lévy Y., Thiébaut R. et al., 2019/05. The lancet. HIV, 6 (5) pp. e334-e340. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2A5E5DD64601]
 
PERISCOPE: road towards effective control of pertussis.
PERISCOPE Consortium, Diavatopoulos D.A., 2019/05. The Lancet. Infectious diseases, 19 (5) pp. e179-e186. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3850F0D40112]
 
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.
Julg B., Dee L., Ananworanich J., Barouch D.H., Bar K., Caskey M., Colby D.J., Dawson L., Dong K.L., Dubé K. et al., 2019/04. The lancet. HIV, 6 (4) pp. e259-e268. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D9BACB56B9AE]
HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses.
Amelio P., Portevin D., Hella J., Reither K., Kamwela L., Lweno O., Tumbo A., Geoffrey L., Ohmiti K., Ding S. et al., 2019/03/01. Journal of virology, 93 (5). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0A2A8987D545]
 
Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
Asbach B., Kibler K.V., Köstler J., Perdiguero B., Yates N.L., Stanfield-Oakley S., Tomaras G.D., Kao S.F., Foulds K.E., Roederer M. et al., 2019/02/01. Journal of virology, 93 (3). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_011979DE2022]
 
Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.
Kibler K.V., Asbach B., Perdiguero B., García-Arriaza J., Yates N.L., Parks R., Stanfield-Oakley S., Ferrari G., Montefiori D.C., Tomaras G.D. et al., 2019/02/01. Journal of virology, 93 (3). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C7AB149CAD1E]
Comparative analysis and generation of a robust HIV-1 DNA quantification assay.
Thomas J., Ruggiero A., Procopio F.A., Pantaleo G., Paxton W.A., Pollakis G., 2019/01. Journal of virological methods, 263 pp. 24-31. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_62022265AD93]
Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
Perdiguero B., Gómez C.E., García-Arriaza J., Sánchez-Corzo C., Sorzano CÓS, Wilmschen S., von Laer D., Asbach B., Schmalzl C., Peterhoff D. et al., 2019. Frontiers in immunology, 10 p. 2941. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_61B1B7E651FD]
Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination.
Cram J.A., Fiore-Gartland A.J., Srinivasan S., Karuna S., Pantaleo G., Tomaras G.D., Fredricks D.N., Kublin J.G., 2019. PloS one, 14 (12) pp. e0225622. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F7483D5519F1]
Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.
Rockstroh J.K., Asmuth D., Pantaleo G., Clotet B., Podzamczer D., van Lunzen J., Arastéh K., Mitsuyasu R., Peters B., Silvia N. et al., 2019. PloS one, 14 (1) pp. e0210965. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_70A55586092A]
2018
CD32+ and PD-1+ Lymph Node CD4 T Cells Support Persistent HIV-1 Transcription in Treated Aviremic Individuals
Noto A., Procopio F.A., Banga R., Suffiotti M., Corpataux J.M., Cavassini M., Riva A., Fenwick C., Gottardo R., Perreau M. et al., 2018/10/15. Journal of virology, 92 (20). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EFF772664CD3]
 
Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial.
Mombelli M., Rettby N., Perreau M., Pascual M., Pantaleo G., Manuel O., 2018/10/01. Vaccine, 36 (41) pp. 6163-6169. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_38C298B3CEB2]
 
TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs.
Cheng L., Wang Q., Li G., Banga R., Ma J., Yu H., Yasui F., Zhang Z., Pantaleo G., Perreau M. et al., 2018/10/01. The Journal of clinical investigation, 128 (10) pp. 4387-4396. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A76F3B73E54A]
Hyperglycaemia is inversely correlated with live M. bovis BCG-specific CD4+ T cell responses in Tanzanian adults with latent or active tuberculosis
Boillat-Blanco N., Tumbo A.N., Perreau M., Amelio P., Ramaiya K.L., Mganga M., Schindler C., Gagneux S., Reither K., Probst-Hensch N. et al., 2018/06. Immunity, inflammation and disease, 6 (2) pp. 345-353. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E678D6B1F88E]
HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.
Yates N.L., deCamp A.C., Korber B.T., Liao H.X., Irene C., Pinter A., Peacock J., Harris L.J., Sawant S., Hraber P. et al., 2018/04/15. Journal of virology, 92 (8) pp. e01843-17 . Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7D182EB82921]
 
Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates.
Saunders K.O., Santra S., Parks R., Yates N.L., Sutherland L.L., Scearce R.M., Balachandran H., Bradley T., Goodman D., Eaton A. et al., 2018/04/15. Journal of virology, 92 (8) p. 1. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6319393AA06F]
Comparison of CyTOF assays across sites: Results of a six-center pilot study.
Leipold M.D., Obermoser G., Fenwick C., Kleinstuber K., Rashidi N., McNevin J.P., Nau A.N., Wagar L.E., Rozot V., Davis M.M. et al., 2018/02. Journal of immunological methods, 453 pp. 37-43. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_52B838044D38]
Antibodies to <i>Chlamydia trachomatis</i> and reproductive health issues in women with SLE: a case-control study.
Santos A., Greub G., Aeby S., Wunder D., Pantaleo G., Ribi C., 2018. Lupus science & medicine, 5 (1) pp. e000293. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B997988DA92E]
Effect of high-intensity versus low-intensity praziquantel treatment on HIV disease progression in HIV and <i>Schistosoma mansoni</i> co-infected patients: a randomised controlled trial.
Abaasa A., Asiki G., Obuku Ekii A., Wanyenze J., Pala P., J van Dam G., L A M Corstjens P., Hughes P., Ding S., Pantaleo G. et al., 2018. Wellcome open research, 3 p. 81. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_147F5B316B25]
2017
 
Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs.
Tapia G., Højen J.F., Ökvist M., Olesen R., Leth S., Nissen S.K., VanBelzen D.J., O'Doherty U., Mørk A., Krogsgaard K. et al., 2017/12. The Journal of infection, 75 (6) pp. 555-571. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8AF88D92E5B7]
Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial.
Huang Y., Pantaleo G., Tapia G., Sanchez B., Zhang L., Trondsen M., Hovden A.O., Pollard R., Rockstroh J., Ökvist M. et al., 2017/10. EBioMedicine, 24 pp. 195-204. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CB6E21477314]
 
Targeted Immune Interventions for an HIV-1 Cure.
Perreau M., Banga R., Pantaleo G., 2017/10. Trends in molecular medicine, 23 (10) pp. 945-961. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CCFE48672672]
A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.
Meador L.R., Kessans S.A., Kilbourne J., Kibler K.V., Pantaleo G., Roderiguez M.E., Blattman J.N., Jacobs B.L., Mor T.S., 2017/07. Virology, 507 pp. 242-256. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_38561B71F7B3]
Mixed Th1 and Th2 Mycobacterium tuberculosis-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania.
Amelio P., Portevin D., Reither K., Mhimbira F., Mpina M., Tumbo A., Nickel B., Marti H., Knopp S., Ding S. et al., 2017/07. PLoS neglected tropical diseases, 11 (7) pp. e0005817. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_843AC43D04A8]
 
B-cell abnormalities and impact on antibody response in HIV infection.
Noto A., Pantaleo G., 2017/05. Current opinion in HIV and AIDS, 12 (3) pp. 203-208. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B4C8B32F3BDB]
 
HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J., Perdiguero B., Heeney J.L., Seaman M.S., Montefiori D.C., Yates N.L., Tomaras G.D., Ferrari G., Foulds K.E., Roederer M. et al., 2017/05/01. Journal of virology, 91 (9). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4AB7B2C38624]
 
Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
Zurawski G., Shen X., Zurawski S., Tomaras G.D., Montefiori D.C., Roederer M., Ferrari G., Lacabaratz C., Klucar P., Wang Z. et al., 2017/05/01. Journal of virology, 91 (9). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_57668F63DF01]
 
Identification of a novel HLA-B*18 allele, B*18:119, using sequence-based typing in a caucasoid individual.
André C., Pantaleo G., Aubert V., 2017/04. HLA, 89 (4) pp. 244-245. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2543D5E2841D]
Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect™.
Vescovo P., Rettby N., Ramaniraka N., Liberman J., Hart K., Cachemaille A., Piveteau L.D., Zanoni R., Bart P.A., Pantaleo G., 2017/03/27. Vaccine, 35 (14) pp. 1782-1788. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A7C81D7FFA31]
 
Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies.
Petrovas C., Ferrando-Martinez S., Gerner M.Y., Casazza J.P., Pegu A., Deleage C., Cooper A., Hataye J., Andrews S., Ambrozak D. et al., 2017/01/18. Science translational medicine, 9 (373) p. 373. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6300DD2A65E6]
2016
 
Determinants of HIV-1 broadly neutralizing antibody induction.
Rusert P., Kouyos R.D., Kadelka C., Ebner H., Schanz M., Huber M., Braun D.L., Hozé N., Scherrer A., Magnus C. et al., 2016/11. Nature medicine, 22 (11) pp. 1260-1267. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E6B22356AA9D]
 
Therapeutic vaccines and immunological intervention in HIV infection: a paradigm change.
Pantaleo G., Levy Y., 2016/11. Current opinion in HIV and AIDS, 11 (6) pp. 576-584. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_369C392ACCBE]
 
Correlating HIV tropism with immunological response under combination antiretroviral therapy.
Bader J., Schöni-Affolter F., Böni J., Gorgievski-Hrisoho M., Martinetti G., Battegay M., Klimkait T., Swiss HIV Cohort Study, 2016/09. HIV medicine, 17 (8) pp. 615-622. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_34F6E591ED44]
Effect of Schistosoma mansoni Infection on Innate and HIV-1-Specific T-Cell Immune Responses in HIV-1-Infected Ugandan Fisher Folk.
Obuku A.E., Asiki G., Abaasa A., Ssonko I., Harari A., van Dam G.J., Corstjens P.L., Joloba M., Ding S., Mpendo J. et al., 2016/07. AIDS research and human retroviruses, 32 (7) pp. 668-675. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FB39146F35F0]
 
PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals.
Banga R., Procopio F.A., Noto A., Pollakis G., Cavassini M., Ohmiti K., Corpataux J.M., de Leval L., Pantaleo G., Perreau M., 2016/07. Nature medicine, 22 (7) pp. 754-761. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FCD5348987A9]
 
Clinically-relevant threshold of preformed donor-specific anti-HLA antibodies in kidney transplantation.
Salvadé I., Aubert V., Venetz J.P., Golshayan D., Saouli A.C., Matter M., Rotman S., Pantaleo G., Pascual M., 2016/06. Human immunology, 77 (6) pp. 483-489. Peer-reviewed.
[DOI][Pmid][serval:BIB_04243BC5CAD3]
 
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
Asbach B., Kliche A., Köstler J., Perdiguero B., Esteban M., Jacobs B.L., Montefiori D.C., LaBranche C.C., Yates N.L., Tomaras G.D. et al., 2016/04. Journal of virology, 90 (8) pp. 4133-4149. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C0177FF88AB3]
 
A case for preART-adjusted endpoints in HIV therapeutic vaccine trials.
Huang Y., Zhang L., Jolliffe D., Hovden A.O., Ökvist M., Pantaleo G., Sommerfelt M.A., 2016. Vaccine, 34 (10) pp. 1282-1288. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_59B96F151F7F]
Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques.
Zurawski G., Zurawski S., Flamar A.L., Richert L., Wagner R., Tomaras G.D., Montefiori D.C., Roederer M., Ferrari G., Lacabaratz C. et al., 2016. Plos One, 11 (4) pp. e0153484. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_980FC2E7134A]
 
Unite forces to validate biomarkers in the quest for lasting HIV remission.
Rokx C., Vella S., Pantaleo G., Lévy Y., Boucher C.A., 2016. Aids, 30 (11) pp. 1859-1860. Peer-reviewed.
[DOI][Pmid][serval:BIB_69406F112241]
2015
COMPASS identifies T-cell subsets correlated with clinical outcomes.
Lin L., Finak G., Ushey K., Seshadri C., Hawn T.R., Frahm N., Scriba T.J., Mahomed H., Hanekom W., Bart P.A. et al., 2015/06. Nature biotechnology, 33 (6) pp. 610-616. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8FADB11D7063]
 
Capacity for science in sub-Saharan Africa.
Elliott A., Nerima B., Bagaya B., Kambugu A., Joloba M., Cose S., Pantaleo G., Yazdanbakhsh M., Mabey D., Dunne D. et al., 2015. Lancet, 385 (9986) pp. 2435-2437.
[DOI][WoS][Pmid][serval:BIB_FED7CD1753BD]
Combined Use of Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis.
Rozot V., Patrizia A., Vigano S., Mazza-Stalder J., Idrizi E., Day C.L., Perreau M., Lazor-Blanchet C., Ohmiti K., Goletti D. et al., 2015. Clinical Infectious Diseases, 60 (3) pp. 432-437. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_35203E0F848B]
 
Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
Hulot S.L., Korber B., Giorgi E.E., Vandergrift N., Saunders K.O., Balachandran H., Mach L.V., Lifton M.A., Pantaleo G., Tartaglia J. et al., 2015. Journal of Virology, 89 (12) pp. 6462-6480. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9ABE1A5A8729]
 
Emerging single-cell technologies in immunology.
Herderschee J., Fenwick C., Pantaleo G., Roger T., Calandra T., 2015. Journal of Leukocyte Biology, 98 (1) pp. 23-32. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B577FB613E4C]
 
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
García-Arriaza J., Perdiguero B., Heeney J., Seaman M., Montefiori D.C., Labranche C., Yates N.L., Shen X., Tomaras G.D., Ferrari G. et al., 2015. Journal of Virology, 89 (16) pp. 8525-8539. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BC8EC27AA24B]
Identification and visualization of multidimensional antigen-specific T-cell populations in polychromatic cytometry data.
Lin L., Frelinger J., Jiang W., Finak G., Seshadri C., Bart P.A., Pantaleo G., McElrath J., DeRosa S., Gottardo R., 2015. Cytometry. Part A, 87 (7) pp. 675-682. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A190F236B1C2]
 
Immune correlates of vaccine protection against HIV-1 acquisition.
Corey L., Gilbert P.B., Tomaras G.D., Haynes B.F., Pantaleo G., Fauci A.S., 2015. Science Translational Medicine, 7 (310) pp. 310rv7. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8CEE6DB353F7]
Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.
Delaloye J., Filali-Mouhim A., Cameron M.J., Haddad E.K., Harari A., Goulet J.P., Gomez C.E., Perdiguero B., Esteban M., Pantaleo G. et al., 2015. Journal of Virology, 89 (7) pp. 3819-3832. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3F54B19290C2]
 
NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.
Di Pilato M., Mejías-Pérez E., Zonca M., Perdiguero B., Gómez C.E., Trakala M., Nieto J., Nájera J.L., S Sorzano C.O., Combadière C. et al., 2015. Proceedings of the National Academy of Sciences of the United States of America, 112 (11) pp. E1333-E1342. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C6CDF3DAF499]
Schistosoma mansoni and HIV acquisition in fishing communities of Lake Victoria, Uganda: a nested case-control study.
Ssetaala A., Nakiyingi-Miiro J., Asiki G., Kyakuwa N., Mpendo J., Van Dam G.J., Corstjens P.L., Pala P., Nielsen L., Bont J. et al., 2015. Tropical Medicine and International Health, 20 (9) pp. 1190-1195. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EFE5F4BAAACE]
 
Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1.
Mooij P., Koopman G., Drijfhout J.W., Nieuwenhuis I.G., Beenhakker N., Koestler J., Bogers W.M., Wagner R., Esteban M., Pantaleo G. et al., 2015. Journal of General Virology, 96 (Pt 6) pp. 1478-1483. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_295841777C34]
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
Søgaard O.S., Graversen M.E., Leth S., Olesen R., Brinkmann C.R., Nissen S.K., Kjaer A.S., Schleimann M.H., Denton P.W., Hey-Cunningham W.J. et al., 2015. Plos Pathogens, 11 (9) pp. e1005142. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CFC707BF32ED]
 
Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates.
Shen X., Duffy R., Howington R., Cope A., Sadagopal S., Park H., Pal R., Kwa S., Ding S., Yang O.O. et al., 2015. Journal of Virology, 89 (16) pp. 8643-8650. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1DE3F28356D7]
 
Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles.
Perdiguero B., Gómez C.E., Cepeda V., Sánchez-Sampedro L., García-Arriaza J., Mejías-Pérez E., Jiménez V., Sánchez C., Sorzano C.Ó., Oliveros J.C. et al., 2015. Journal of Virology, 89 (2) pp. 970-988. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5051C6A40F15]
2014
 
Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.
Jilek S., Mathias A., Canales M., Lysandropoulos A., Pantaleo G., Schluep M., Du Pasquier R.A., 2014/06. Multiple sclerosis (Houndmills, Basingstoke, England), 20 (7) pp. 837-842. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_75F2F83A31AE]
 
A 3 years retrospective study of survival for zirconia-based single crowns fabricated from intraoral digital impressions.
Gherlone E., Mandelli F., Capparè P., Pantaleo G., Traini T., Ferrini F., 2014. Journal of Dentistry, 42 (9) pp. 1151-1155. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BEAA31E109D6]
 
Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function.
Castelli R., Deliliers G.L., Colombo R., Moreo G., Gallipoli P., Pantaleo G., 2014. Annals of Hematology, 93 (9) pp. 1523-1529.
[DOI][Pmid][serval:BIB_964145E80AEE]
 
Bivalent NYVAC-based Vaccine Candidates against HIV/AIDS Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as VLPs.
Perdiguero B., Gómez C.E., Cepeda M.V., Sánchez-Sampedro L., García-Arriaza J., Mejías-Pérez E., Jiménez V., Sánchez C., Sorzano C.O., Delaloye J. et al., 2014. pp. A119 dans Aids Research and Human Retroviruses. Peer-reviewed.
[DOI][Pmid][serval:BIB_A173C82FBCD3]
 
Bone and soft tissue non-Hodgkin lymphoma of the maxillofacial area: report of two cases, literature review and new therapeutic strategies.
Cortese A., Pantaleo G., Ferrara I., Vatrella A., Cozzolino I., Di Crescenzo V., Amato M., 2014. International journal of surgery (London, England), 12 Suppl 2 pp. S23-8.
[DOI][Pmid][serval:BIB_2764F2755C75]
Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders.
Perreau M., Vigano S., Bellanger F., Pellaton C., Buss G., Comte D., Roger T., Lacabaratz C., Bart P.A., Levy Y. et al., 2014. Journal of Experimental Medicine, 211 (10) pp. 2033-2045. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4C2E49D53264]
HIV-1 superinfection with a triple-class drug-resistant strain in a patient successfully controlled with antiretroviral treatment.
Castro E., Zhao H., Cavassini M., Mullins J.I., Pantaleo G., Bart P.A., 2014. Aids, 28 (12) pp. 1840-1844. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9A45B5FC5D96]
 
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.
Bart P.A., Huang Y., Karuna S.T., Chappuis S., Gaillard J., Kochar N., Shen X., Allen M.A., Ding S., Hural J. et al., 2014. Journal of Clinical Investigation, 124 (11) pp. 4843-4856.
[DOI][WoS][Pmid][serval:BIB_CED7CDA79111]
 
Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
Muyanja E., Ssemaganda A., Ngauv P., Cubas R., Perrin H., Srinivasan D., Canderan G., Lawson B., Kopycinski J., Graham A.S. et al., 2014. Journal of Clinical Investigation, 124 (7) pp. 3147-3158.
[DOI][WoS][Pmid][serval:BIB_A388598F9F16]
 
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
Pollard R.B., Rockstroh J.K., Pantaleo G., Asmuth D.M., Peters B., Lazzarin A., Garcia F., Ellefsen K., Podzamczer D., van Lunzen J. et al., 2014. Lancet Infectious Diseases, 14 (4) pp. 291-300.
[DOI][WoS][Pmid][serval:BIB_BEEE667D2F5B]
 
The immune space: a concept and template for rationalizing vaccine development.
Manrique A., Adams E., Barouch D.H., Fast P., Graham B.S., Kim J.H., Kublin J.G., McCluskey M., Pantaleo G., Robinson H.L. et al., 2014. Aids Research and Human Retroviruses, 30 (11) pp. 1017-1022. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9F5453339A90]
Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study.
Drescher S.M., von Wyl V., Yang W.L., Böni J., Yerly S., Shah C., Aubert V., Klimkait T., Taffé P., Furrer H. et al., 2014. Clinical Infectious Diseases, 58 (2) pp. 285-294.
[URN][DOI][WoS][Pmid][serval:BIB_9722D8509BAC]
2013
Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C.
Perdiguero B., Gómez C.E., Di Pilato M., Sorzano C.O., Delaloye J., Roger T., Calandra T., Pantaleo G., Esteban M., 2013. Plos One, 8 (9) pp. e74831. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E338A0FB5AA2]
 
Effort processes in achieving performance outcomes: interrelations among and roles of core constructs.
Wright R.A., Pantaleo G., 2013. Behavioral and Brain Sciences, 36 (6) pp. 705-706.
[DOI][WoS][Pmid][serval:BIB_600D6DF7FFC0]
Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production.
Perreau M., Savoye A.L., De Crignis E., Corpataux J.M., Cubas R., Haddad E.K., De Leval L., Graziosi C., Pantaleo G., 2013. Journal of Experimental Medicine, 210 (1) pp. 143-156. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6855C69852B5]
 
Immune response to HIV.
Perreau M., Levy Y., Pantaleo G., 2013. Current Opinion in HIV and Aids, 8 (4) pp. 333-340.
[DOI][WoS][Pmid][serval:BIB_C74E1437AA13]
Inadequate T follicular cell help impairs B cell immunity during HIV infection.
Cubas R.A., Mudd J.C., Savoye A.L., Perreau M., van Grevenynghe J., Metcalf T., Connick E., Meditz A., Freeman G.J., Abesada-Terk G. et al., 2013. Nature Medicine, 19 (4) pp. 494-499. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F10C91F4362C]
MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects.
Jilek S., Schluep M., Pantaleo G., Du Pasquier R.A., 2013. Neurological Sciences, 34 (4) pp. 539-543.
[URN][DOI][WoS][Pmid][serval:BIB_4187CB3E957E]
 
Multicenter evaluation of the elecsys® anti-HCV II assay for the diagnosis of hepatitis C virus infection.
Esteban J.I., van Helden J., Alborino F., Bürgisser P., Cellerai C., Pantaleo G., Eiras A., Rodriguez M.I., Ghisetti V., Gleich M. et al., 2013. Journal of Medical Virology, 85 (8) pp. 1362-1368.
[DOI][WoS][Pmid][serval:BIB_47F08714BB89]
 
Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease.
Rozot V., Vigano S., Mazza-Stalder J., Idrizi E., Day C.L., Perreau M., Lazor-Blanchet C., Petruccioli E., Hanekom W., Goletti D. et al., 2013. European Journal of Immunology, 43 (6) pp. 1568-1577.
[DOI][WoS][Pmid][serval:BIB_7269592AD615]
Performance evaluation of a new fourth-generation HIV combination antigen-antibody assay.
Mühlbacher A., Schennach H., van Helden J., Hebell T., Pantaleo G., Bürgisser P., Cellerai C., Permpikul P., Rodriguez M.I., Eiras A. et al., 2013. Medical Microbiology and Immunology, 202 (1) pp. 77-86.
[URN][DOI][WoS][Pmid][serval:BIB_95AE603EC052]
Rapid Perturbation in Viremia Levels Drives Increases in Functional Avidity of HIV-specific CD8 T Cells.
Viganò S., Bellutti Enders F., Miconnet I., Cellerai C., Savoye A.L., Rozot V., Perreau M., Faouzi M., Ohmiti K., Cavassini M. et al., 2013. Plos Pathogens, 9 (7) pp. e1003423.
[URN][DOI][WoS][Pmid][serval:BIB_D20B27FA77D4]
 
The functional and structural neural basis of individual differences in loss aversion.
Canessa N., Crespi C., Motterlini M., Baud-Bovy G., Chierchia G., Pantaleo G., Tettamanti M., Cappa S.F., 2013. Journal of Neuroscience, 33 (36) pp. 14307-14317.
[DOI][WoS][Pmid][serval:BIB_9819866521F0]
 
Thirty years of HIV: what have we learned?
Cooper D.A., Pantaleo G., 2013. Current Opinion in HIV and Aids, 8 (4) pp. 304-305.
[DOI][WoS][Pmid][serval:BIB_F9A547EBBED2]
 
Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts.
Marais B.J., Lönnroth K., Lawn S.D., Migliori G.B., Mwaba P., Glaziou P., Bates M., Colagiuri R., Zijenah L., Swaminathan S. et al., 2013. Lancet Infectious Diseases, 13 (5) pp. 436-448.
[DOI][WoS][Pmid][serval:BIB_65DCE96B1D2C]
 
Vaccine and immunotherapeutic interventions.
Pantaleo G., Lévy Y., 2013. Current Opinion in Hiv and Aids, 8 (3) pp. 236-242.
[DOI][WoS][Pmid][serval:BIB_5D73CB52384C]
2012
A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity.
Pattacini L., Mize G.J., Graham J.B., Fluharty T.R., Graham T.M., Lingnau K., Wizel B., Perdiguero B., Esteban M., Pantaleo G. et al., 2012. Plos One, 7 (7) pp. e42163.
[URN][DOI][WoS][Pmid][serval:BIB_E677EE9F9A8A]
Carriers of the fragile X mental retardation 1 (FMR1) premutation allele present with increased levels of cytokine IL-10.
Marek D., Papin S., Ellefsen K., Niederhauser J., Isidor N., Ransijn A., Poupon L., Spertini F., Pantaleo G., Bergmann S. et al., 2012. Journal of Neuroinflammation, 9 p. 238. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_ADF180AFD031]
Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.
Perdiguero B., Gómez C.E., Nájera J.L., Sorzano C.O., Delaloye J., González-Sanz R., Jiménez V., Roger T., Calandra T., Pantaleo G. et al., 2012. Plos One, 7 (10) pp. e48524. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CA881424A3B7]
Functional avidity: a measure to predict the efficacy of effector T cells?
Viganò S., Utzschneider D.T., Perreau M., Pantaleo G., Zehn D., Harari A., 2012. Clinical and Developmental Immunology, 2012 p. 153863. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B0CB84A1CD5B]
 
HLA-B7-Restricted EBV-Specific CD8+ T Cells Are Dysregulated in Multiple Sclerosis.
Jilek S., Schluep M., Harari A., Canales M., Lysandropoulos A., Zekeridou A., Pantaleo G., Du Pasquier R.A., 2012. Journal of Immunology, 188 (9) pp. 4671-4680. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A0D2159CC0F6]
 
Impairment of JCV-specific T-cell response by corticotherapy: Effect on PML-IRIS management?
Antoniol C., Jilek S., Schluep M., Mercier N., Canales M., Le Goff G., Campiche C., Pantaleo G., Du Pasquier R.A., 2012. Neurology, 79 (23) pp. 2258-2264.
[DOI][WoS][Pmid][serval:BIB_703F31D7E9A0]
 
Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.
Vardas E., Stanescu I., Leinonen M., Ellefsen K., Pantaleo G., Valtavaara M., Ustav M., Reijonen K., 2012. Vaccine, 30 (27) pp. 4046-4054.
[DOI][WoS][Pmid][serval:BIB_AB309B04B63D]
 
Modulation of human memory T-cell function by different antigen-presenting cells.
Perreau M., Welles H.C., Harari A., Calandra T., Roger T., Pantaleo G., 2012. European Journal of Immunology, 42 (3) pp. 799-802.
[DOI][WoS][Pmid][serval:BIB_426696050FC2]
 
Mycobacterium tuberculosis-specific CD8 T cells are functionally and phenotypically different between latent infection and active disease
Rozot V., Vigano S., Mazza-Stalder J., Perreau M., Goletti D., Bart P. A., Nicod L., Pantaleo G., Harari A., 2012. p. 598 dans European Congress of Immunology, Immunology.
[WoS][serval:BIB_D7303CF13CEC]
 
Nonrandom Distribution of Cryptic Repeating Triplets of Purines and Pyrimidines (RNY)(n) in gp120 of HIV Type1.
De Crignis E., Guglietta S., Foley B.T., Negroni M., Di Narzo A.F., Waelti Da Costa V., Cavassini M., Bart P.A., Pantaleo G., Graziosi C., 2012. Aids Research and Human Retroviruses, 28 (5) pp. 493-504.
[DOI][WoS][Pmid][serval:BIB_E7E373E5CDE0]
 
NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients.
Harari A., Rozot V., Cavassini M., Enders F.B., Vigano S., Tapia G., Castro E., Burnet S., Lange J., Moog C. et al., 2012. European Journal of Immunology, 42 (11) pp. 3038-3048.
[DOI][WoS][Pmid][serval:BIB_0D93650C7F77]
Positive and negative regulation of cellular immune responses in physiologic conditions and diseases.
Viganò S., Perreau M., Pantaleo G., Harari A., 2012. Clinical and Developmental Immunology, 2012 p. 485781.
[URN][DOI][WoS][Pmid][serval:BIB_4F81E9CDB066]
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
Gómez C.E., Perdiguero B., Jiménez V., Filali-Mouhim A., Ghneim K., Haddad E.K., Quakkelaar E.D., Quakkerlaar E.D., Delaloye J., Harari A. et al., 2012. Plos One, 7 (4) pp. e35485.
[URN][DOI][WoS][Pmid][serval:BIB_C791C445724A]
 
Systems biology in the development of HIV vaccines.
Haddad E.K., Pantaleo G., 2012. Current Opinion In Hiv and Aids, 7 (1) pp. 44-49. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D9A012FB0528]
 
The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes.
Perreau M., Welles H.C., Pellaton C., Gjoksi B., Potin L., Martin R., Harari A., Bett A., Casimiro D., Gall J. et al., 2012. Journal of Virology, 86 (11) pp. 6279-6285.
[DOI][WoS][Pmid][serval:BIB_B4299141A4E6]
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities.
McNerney R., Maeurer M., Abubakar I., Marais B., McHugh T.D., Ford N., Weyer K., Lawn S., Grobusch M.P., Memish Z. et al., 2012. Journal of Infectious Diseases, 205 (Suppl. 2) pp. S147-S158.
[URN][DOI][WoS][Pmid][serval:BIB_F65424B09DBF]
2011
 
Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease.
Harari A., Rozot V., Bellutti Enders F., Perreau M., Mazza-Stalder J.M., Nicod L.P., Cavassini M., Calandra T., Blanchet C.L., Jaton K. et al., 2011/03. Nature medicine, 17 (3) pp. 372-376. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C47C605FFBCF]
 
A Phase IIB, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in HIV-1-infected Patients
Rockstroh J.K., Pantaleo G., Pollard R., van Lunzen J., Asmuth D., Peters B., Podzamczer D., Lazzarin A., Ellefsen-Lavoie K., Baksaas I. et al., 2011. pp. A129-A130 dans AIDS Vaccine 2011 Conference, Aids Research and Human Retroviruses. Peer-reviewed.
[WoS][serval:BIB_A89095C1B5AA]
 
Boosting of Replication Competent NYVAC Primed HIV-1-Specific T-Cell Responses by HIV Synthetic Long Peptides (SLP)
Mooij P., Nieuwenhuis I., Beenhakker N., Quakkelaar E.D., Heeney J.L., Esteban M., Jacobs B., Pantaleo G., Bogers W.M., Melief C. et al., 2011. pp. A96-A97 dans AIDS Vaccine 2011 Conference, Aids Research and Human Retroviruses. Peer-reviewed.
[WoS][serval:BIB_745931C2525D]
 
DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell Responses in Intestinal Mucosa
Perreau M., Welles H.C., Harari A., Hall O., Martin R., Maillard M., Dorta G., Bart P., Kremer E.J., Tartaglia J. et al., 2011. pp. A3 dans AIDS Vaccine 2011 Conference, Aids Research and Human Retroviruses. Peer-reviewed.
[WoS][serval:BIB_5A1662127306]
 
DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa.
Perreau M., Welles H.C., Harari A., Hall O., Martin R., Maillard M., Dorta G., Bart P.A., Kremer E.J., Tartaglia J. et al., 2011. Journal of Virology, 85 (19) pp. 9854-9862.
[DOI][WoS][Pmid][serval:BIB_B8BC78EDCB21]
Early and Prolonged Antiretroviral Therapy Is Associated with an HIV-1-Specific T-Cell Profile Comparable to That of Long-Term Non-Progressors.
Cellerai C., Harari A., Stauss H., Yerly S., Geretti A.M., Carroll A., Yee T., Ainsworth J., Williams I., Sweeney J. et al., 2011. Plos One, 6 (4) pp. e18164.
[URN][DOI][WoS][Pmid][serval:BIB_44B55F68B8CD]
 
Effect of vitamin D on EBV-specific CD8+T cells in patients with early multiple sclerosis
Lysandropoulos A., Schluep M., Jaquiery E., Jilek S., Canales M., Pantaleo G., Du Pasquier R., 2011. p. 117 dans Annual Congress SGAI-SSAI, Advances in immunology and allergology: from research to diagnosis and therapy, Allergologie. Peer-reviewed.
[WoS][serval:BIB_8F68600C08F3]
HIV-1 vaccines and adaptive trial designs.
Corey L., Nabel G.J., Dieffenbach C., Gilbert P., Haynes B.F., Johnston M., Kublin J., Lane H.C., Pantaleo G., Picker L.J. et al., 2011. Science Translational Medicine, 3 (79) pp. 79ps13.
[URN][DOI][WoS][Pmid][serval:BIB_F0E24EC6F027]
 
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates.
Flynn B.J., Kastenmüller K., Wille-Reece U., Tomaras G.D., Alam M., Lindsay R.W., Salazar A.M., Perdiguero B., Gomez C.E., Wagner R. et al., 2011. Proceedings of the National Academy of Sciences of the United States of America, 108 (17) pp. 7131-7136.
[DOI][WoS][Pmid][serval:BIB_C489D6A0A48E]
 
Impact of Pre-Existing Immunity on the Selection of Rare Adenovirus Vector Candidates: Implications for HIV Vaccine Development
Perreau M., Welles H.C., Harari A., Potin L., Martin R., Bibert S., Roger T., Calandra T., Bett A., Gall J. et al., 2011. pp. A109 dans AIDS Vaccine 2011 Conference, Aids Research and Human Retroviruses. Peer-reviewed.
[WoS][serval:BIB_52448710FD7A]
 
Improved immunogenicity against HIV-1 clade C antigens by using NYVAC-C with restored replication competence.
Mooij P., Nieuwenhuis I., Beenhakker N., Hofman S., Esteban M., Jacobs B., Kibler K., Koopman K., Bogers W.M.J.M, Pantaleo P. et al., 2011. pp. 265-266 dans AIDS Vaccine 2010, Journal of Medical Primatology. Peer-reviewed.
[WoS][serval:BIB_6BB71B21AD64]
Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors.
Quakkelaar E.D., Redeker A., Haddad E.K., Harari A., McCaughey S.M., Duhen T., Filali-Mouhim A., Goulet J.P., Loof N.M., Ossendorp F. et al., 2011. Plos One, 6 (2) pp. e16819.
[URN][DOI][WoS][Pmid][serval:BIB_38370DD8AB46]
Improved NYVAC-based vaccine vectors.
Kibler K.V., Gomez C.E., Perdiguero B., Wong S., Huynh T., Holechek S., Arndt W., Jimenez V., Gonzalez-Sanz R., Denzler K. et al., 2011. Plos One, 6 (11) pp. e25674.
[URN][DOI][WoS][Pmid][serval:BIB_E7534DDC83F4]
 
La signature immunologique - Nouvel outil diagnostique de la tuberculose active  [Immunological signatures: a new tool to diagnose active tuberculosis disease?].
Rozot V., Perreau M., Harari A., Pantaleo G., 2011. Médecine Sciences, 27 (10) pp. 808-811.
[DOI][WoS][Pmid][serval:BIB_3622C4E9C156]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University